Dr. Wang on Updated Data With Single-Agent Acalabrutinib in MCL

Video

In Partnership With:

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib (Calquence) in relapsed/refractory mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, Wang presented longer-term follow-up data from the pivotal trial that led to the initial FDA approval for the second-generation BTK inhibitor in October 2017. Acalabrutinib is indicated for the treatment of adult patients with MCL who have received at least 1 prior therapy. While the initial data published in Lancet Oncology consisted of 15 months follow-up, the data presented at the meeting were from over 2 years of follow-up.

At a median follow-up of 26.3 months, the overall response rate with acalabrutinib was 81% and appeared to be consistent across subgroups based on tumor bulk. Median duration of response was 26.0 months and median progression-free survival was 20.0 months. The median overall survival (OS) was not yet reached at the time of the presentation, but the estimated 2-year OS rate was 72% with the agent. Acalabrutinib has not yet been tested in a head-to-head study with the first-generation BTK inhibitor ibrutinib (Imbruvica).

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD